https://doi.org/10.4081/ejtm.2025.13787
A randomized interventional study that compares treatments for vitiligo and anti-vitiligo cream
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 26 May 2025
This study aimed to evaluate the efficacy of a novel combination therapy, AVC (Anti-Vitiligo Cream), compared to common treatments for vitiligo. A randomized interventional study was conducted on 1,000 patients with confirmed vitiligo, aged 7–70 years. Participants were divided into five groups (200 patients each): oral prednisolone, Tofacitinib, Ruxolitinib, AVC (Anti-Vitiligo Cream), and AVC combined with Tofacitinib. Outcomes were assessed over two years using the Vitiligo Area Scoring Index (VASI), patient satisfaction scores, and clinical observations. AVC-based therapies (Groups 4 and 5) demonstrated superior efficacy and patient satisfaction compared to other treatments. Group 5 (AVC + Tofacitinib) achieved the highest outcomes, with a mean satisfaction score of 90 (IQR: 85–95) and treatment efficacy significantly higher than Group 1 (p < 0.001). Regression analysis identified treatment outcomes and therapy type as significant predictors of satisfaction. AVC (Anti-Vitiligo Cream), particularly in combination with Tofacitinib, represents a groundbreaking approach for managing vitiligo, providing enhanced efficacy and patient satisfaction. These findings support the potential of AVC-based therapies as a standard treatment option.
Downloads
Ezzedine K, Lim HW, Suzuki T et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 2012;25:E1-13. DOI: https://doi.org/10.1111/j.1755-148X.2012.00997.x
Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol 2012;51:1206-12. DOI: https://doi.org/10.1111/j.1365-4632.2011.05377.x
Picardo M, Dell'Anna ML, Ezzedine K, et al. Vitiligo. Nat Rev Dis Primers 2015;1:15011. DOI: https://doi.org/10.1038/nrdp.2015.11
Shah H, Mehta A, Astik B. Clinical and sociodemographic study of vitiligo. Indian J Dermatol Venereol Leprol 2008;74:701. DOI: https://doi.org/10.4103/0378-6323.45144
Taïeb A, Picardo M; VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007;20:27-35. DOI: https://doi.org/10.1111/j.1600-0749.2006.00355.x
Dahir AM, Thomsen SF. Comorbidities in vitiligo: comprehensive review. Int J Dermatol 2018;57:1157-164. DOI: https://doi.org/10.1111/ijd.14055
Lee JH, Ju HJ, Seo JM, Almurayshid A, et al. Comorbidities in patients with vitiligo: a systematic review and meta-analysis. J Invest Dermatol 2023;143:777-789.e6. DOI: https://doi.org/10.1016/j.jid.2022.10.021
Klisnick A, Schmidt J, Dupond JL, et al. Le vitiligo au cours des syndromes auto-immuns multiples: étude rétrospective de 11 observations et revue de la littérature [Vitiligo in multiple autoimmune syndrome: a retrospective study of 11 cases and a review of the literature]. Rev Med Interne 1998;19:348-52. DOI: https://doi.org/10.1016/S0248-8663(98)80107-0
Bleehen SS. The treatment of vitiligo with topical corticosteroids. Light and electronmicroscopic studies. Br J Dermatol 1976;94:43-50. DOI: https://doi.org/10.1111/j.1365-2133.1976.tb02268.x
Lee JH, Kwon HS, Jung HM, et al. Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis. JAMA Dermatol 2019;155:929-38. DOI: https://doi.org/10.1001/jamadermatol.2019.0696
Kandaswamy S, Akhtar N, Ravindran S, et al. Phototherapy in vitiligo: assessing the compliance, response and patient's perception about disease and treatment. Indian J Dermatol 2013;58:325. DOI: https://doi.org/10.4103/0019-5154.113944
Faraj S, Kemp EH, Gawkrodger DJ. Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors. Clin Exp Immunol 2022;207:27-43. DOI: https://doi.org/10.1093/cei/uxab002
Chang WL, Ko CH. The role of oxidative stress in vitiligo: an update on its pathogenesis and therapeutic implications. Cells 2023;12:936. DOI: https://doi.org/10.3390/cells12060936
Bharti N, Banerjee R, Achalare A, Kasibhatla SM, Joshi R. Estimation of genetic variation in vitiligo associated genes: Population genomics perspective. BMC Genom Data 2024;25:72. DOI: https://doi.org/10.1186/s12863-024-01254-6
Spritz RA, Andersen GH. Genetics of vitiligo. Dermatol Clin 2017;35:245-55. DOI: https://doi.org/10.1016/j.det.2016.11.013
Inoue S, Suzuki T, Sano S, Katayama I. JAK inhibitors for the treatment of vitiligo. J Dermatol Sci 2024;113:86-92. DOI: https://doi.org/10.1016/j.jdermsci.2023.12.008
Qi F, Liu F, Gao L. Janus kinase inhibitors in the treatment of vitiligo: a review. Front Immunol 2021;12:790125. DOI: https://doi.org/10.3389/fimmu.2021.790125
Lee H, Cowan TL, Daniel BS, Murrell DF. A review of JAK and IL-23 inhibitors to treat vitiligo. Australas J Dermatol 2023;64:204–12. DOI: https://doi.org/10.1111/ajd.14001
Karagaiah P, Schwartz RA, Lotti T, et al. Biologic and targeted therapeutics in vitiligo. J Cosmet Dermatol 2023;22:64-73. DOI: https://doi.org/10.1111/jocd.14770
Grossmann MC, Haidari W, Feldman SR. A review on the use of topical ruxolitinib for the treatment of vitiligo. J Drugs Dermatol 2023;22:664-67. DOI: https://doi.org/10.36849/JDD.7268
Tavoletti G, Avallone G, Conforti C, et al. Topical ruxolitinib: A new treatment for vitiligo. J Eur Acad Dermatol Venereol 2023;37:2222-30. DOI: https://doi.org/10.1111/jdv.19162
Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet 2020;396:110-20. DOI: https://doi.org/10.1016/S0140-6736(20)30609-7
Cervelli V, De Angelis B, Balzani A, et al. Treatment of stable vitiligo by ReCell system. Acta Dermatovenerol Croat 2009;17:273-8.
Cervelli V, Spallone D, Lucarini L, et al. Treatment of stable vitiligo hands by ReCell system: a preliminary report. Eur Rev Med Pharmacol Sci 2010;14:691-4.
Mulekar SV, Ghwish B, Al Issa A, Al Eisa A. Treatment of vitiligo lesions by ReCell vs. conventional melanocyte-keratinocyte transplantation: a pilot study. Br J Dermatol 2008;158:45-9. DOI: https://doi.org/10.1111/j.1365-2133.2007.08216.x
Salloum A, Bazzi N, Maalouf D, Habre M. Microneedling in vitiligo: A systematic review. Dermatol Ther 2020;33:e14297. DOI: https://doi.org/10.1111/dth.14297
Atefi N, Ziaeifar E, Seirafianpour F, et al. Evaluation of efficacy and safety of vitiligo treatment with micro-needling combined with N-Acetylcysteine and micro-needling alone: A double-blinded randomized controlled clinical trial. J Cosmet Dermatol 2024;23:2220-30. DOI: https://doi.org/10.1111/jocd.16274
Konstantinova VA, Olisova OY, Gladko VV, Burova EP. Vitiligo - new treatment approach. Clin Cosmet Investig Dermatol 2019;12:911-7. DOI: https://doi.org/10.2147/CCID.S229175
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191-4. DOI: https://doi.org/10.1001/jama.2013.281053
Sun, Xiu-kun, Sheng, An-qi, Xu, Ai-e, Tofacitinib for the treatment of refractory progressive vitiligo: a retrospective case series. Dermatol Ther 2024,9944826. DOI: https://doi.org/10.1155/2024/9944826
Maghfour J, Hamzavi IH, Mohammad TF. An updated review on systemic and targeted therapies for vitiligo. Dermatol Rev 2022;3:313-25. DOI: https://doi.org/10.1002/der2.166
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.